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Abstract
Introduction:Major gaps exist in the measurement of cannabis exposure. The accuracy of self-reported cannabis
and tobacco dose per joint is poorly characterized and has never been investigated following acute cannabis/
tobacco exposure. Using an innovative ‘‘Roll a Joint’’ paradigm, this study aims to (1) compare estimated and
actual dose of cannabis and tobacco per joint at baseline and (2) examine the acute effects of cannabis and/
or tobacco on estimated and actual dose.
Materials and Methods: We investigated this by using a randomized, double-blind, placebo-controlled cross-
over 2 (active cannabis, placebo cannabis) · 2 (active tobacco, placebo tobacco) design in a laboratory setting.
Participants were 24 recreational cousers of cannabis and tobacco. At baseline, they were asked to measure out
the amount of cannabis and tobacco they would put in an average joint for themselves (dose per joint). Then, on
each of four drug administration sessions, participants were again asked to do this for a joint they would want to
smoke ‘‘right now.’’ Self-reported and actual amount was recorded (g).
Results: At baseline, the estimated amount of cannabis per joint (0.28 – 0.23 g) was double the actual amount
(0.14 – 0.12 g) ( p = 0.003, d = 0.723). No difference emerged between estimated (0.43 – 0.25 g) and actual
(0.35 – 0.15 g) ( p = 0.125) amount of tobacco per joint. Compared to placebo, active cannabis reduced the actual
dose of both cannabis ( p = 0.035) and tobacco ( p < 0.001) they put in a joint. Participants accurately estimated
this reduction for tobacco ( p = 0.014), but not for cannabis ( p = 0.680).
Conclusions: Self-reported dose per joint is accurate for tobacco but dramatically overestimates cannabis expo-
sure and therefore should be viewed with caution. Cannabis administration reduced the amount of cannabis and
tobacco added to joints, suggesting a reduction in dose during a smoking session. The ‘‘Roll A Joint’’ paradigm
should be implemented for better accuracy in assessing dose per joint.
Keywords: cannabis; cannabis use metrics; coadministration; dose; quantity; self-report; tobacco
Introduction
Accurate cannabis use metrics are essential for assess-
ing the effects of cannabis. In the ﬁeld of alcohol research,
the concept of a ‘‘standard unit’’ exists as a measure of
consumption. However, there is no equivalent for can-
nabis and self-report measures of cannabis use are at
best, only weakly correlated with objective measures.1
Such metrics are used mainly as a proxy for exposure
to delta-9-tetrahydrocannabinol (THC), but come
with many caveats. For example, people often share
cannabis and the potency and quantity of the canna-
bis bought, especially where sales are not tolerated,
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are often unknown. Moreover, the quantity of use is
likely to be different across types of users, where recre-
ational users are likely to use less cannabis, and there-
fore potentially more tobacco, than daily users. The
absence of a standardized ‘‘cannabis unit’’ and method-
ological differences between studies hinder direct com-
parisons regarding the effects of cannabis.2–5 Moreover,
the role of frequency of use is often overemphasized at
the expense of quantity (e.g., amount of cannabis used
per day, per joint, or joints per gram), which is also a
predictor of problematic use.1,6–8
Another major issue is that worldwide, cannabis use
is strongly associated with tobacco use.9,10 Particularly
in Europe, cannabis is most commonly combined with
tobacco into joints as the primary consumption meth-
od.11 In Europe, ‘‘joints’’ typically contain a mixture of
cannabis and tobacco (and are interchangeably also re-
ferred to as ‘‘spliffs’’). Hereafter, we refer to joints as
a mixture of cannabis and tobacco; however, we ac-
knowledge that in the United States, joints typically
do not contain tobacco.12 Adding nicotine to cannabis
may modify its dose by increasing the amount of THC
released by almost half13 as well as affecting the subjec-
tive experience14,15 and cognitive effects of cannabis.15,16
Combining cannabis and tobacco in joints thus exposes
users to tobacco, potentially leading to a vulnerability to
both nicotine and cannabis dependence.17,18 Further-
more, cannabis users titrate (adjust) their dose based
on the potency of cannabis therefore modifying total
THC exposure.19,20 However, thus far, whether cannabis
users also titrate their dose to tobacco content has not
been investigated.
Two previous studies have investigated dose per
joint using a cannabis substitute.21,22 The ﬁrst did not
measure tobacco21; the other used the same substitute
to measure both cannabis and tobacco (which have dif-
ferent weights)22 and neither was conducted with cous-
ers who smoke joints, where this issue is particularly
pertinent.11 In one Dutch study, van der Pol et al.1 es-
timated dose per joint using actual cannabis, however,
the amount of tobacco was not estimated. Moreover,
there has been no research to date investigating how
acute intoxication may inﬂuence self-reported and
actual dose per joint. To maximize the ecological rele-
vance of this laboratory study, our ‘‘Roll a Joint’’ proce-
dure used a typical brand of rolling tobacco and a
cannabis placebo, produced from active cannabis to
contain less than 0.1% THC (but with the same terpene
content, so it retains the look and smells of cannabis).
We ﬁrst aimed to compare peoples’ estimated and
actual dose of cannabis and tobacco in joints. Second,
we aimed to investigate how estimated and actual
dose per joint is inﬂuenced by smoking cannabis and
tobacco, both individually and combined in joints.
Materials and Methods
Design and participants
Participants took part in a baseline session and then
four acute drug sessions. The acute effects of cannabis
and tobacco, both alone and combined, were evaluated
using a randomized, double-blind, placebo-controlled
four-way crossover design. Previous data from this
study have been published elsewhere on memory and
psychotomimetic effects15 and reward processing.23
The four drug administration sessions (Table 1) were
separated by at least 1-week washout (‡3 times elimi-
nation half-life of THC).24,25 Order of drug treatment
was determined by a balanced Latin square.
Medically and psychiatrically healthy, nondepen-
dent but experienced, cannabis and tobacco cousers
(i.e., ‘‘joint’’ smokers) were recruited from the commu-
nity. Inclusion criteria were as follows: (i) 18–60 years;
(ii) regular use (>once/month but <3 times/week) of
cannabis mixed with tobacco in joints for the previous
6 months; (iii) self-reported ability to smoke one whole
‘‘standard’’ joint; (iv) normal or corrected to normal
vision; (v) ﬂuent English; (vi) self-reported abstinence
from tobacco, cannabis, alcohol, and other drugs for
at least 12 h before each test day; and (vii) alveolar car-
bon monoxide (CO) £6 ppm to conﬁrm no recent
smoking on each test day.12 Exclusion criteria were as
follows: (i) ‡3 on the Cannabis Severity of Dependence
Table 1. Doses for Both Cannabis and Tobacco and Their Matched Placebos Used in the Four Study Conditions
Drug Condition Description
Cannabis Active 66.67mg Bedrobinol (16.1% THC and <1% CBD)
Matched placebo 66.67mg placebo (Bedrocan; 0.07% THC)
Tobacco Active 311mg Marlboro red (15.48mg nicotine, 16mg tar, 0.8mg nicotine yield).
Matched placebo 311mg denicotinized tobacco (Magic 0, 0.04mg/g nicotine yield)
THC, delta-9-tetrahydrocannabinol.
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Scale26; (ii) treatment-seeking for cannabis or tobacco
use, or currently using nicotine replacement therapy
or other cessation pharmacotherapy; (iii) smoking
‡10 cigarettes a day or scoring ‡4 on the Fagerstro¨m
Test of Nicotine Dependence27; (iv) ﬁrst cigarette
smoked within the ﬁrst 3 hours after waking; (v) sig-
niﬁcant respiratory, physical, or clinically diagnosed
learning impairments; (vi) clinically diagnosed schizo-
phrenia or psychosis (or a ﬁrst-degree family member
with either), or substance use disorder; and (vii) illicit
substance use other than cannabis more than once
per week.
‘‘Roll a joint’’ paradigm
This paradigm was designed as an ecological assessment
of participant’s (a) typical dose per joint (at baseline) and
(b) desired dose 1 hour after drug administration of both
cannabis and tobacco. Ground placebo cannabis (which
contains the precise terpene proﬁle of the original strain,
with all cannabinoids removed to <0.2% of dry weight;
available from Bedrocan NL) and rolling tobacco (Amber
Leaf, JTI) were used as substitutes. Two king-sized rolling
papers (108· 44mm; Rizla Blue) were placed in front of
the participant. At baseline, participants were asked to
add the ‘‘amount of cannabis and tobacco they would typ-
ically put in a joint, if the cannabis and tobacco were of
average strength and quality and they could smoke the
whole joint by themselves.’’ One hour after drug ad-
ministration on each drug occasion, participants mea-
sured out cannabis and tobacco in the same manner.
They were asked to estimate how much the amount
of cannabis and tobacco they want to smoke ‘‘right
now.’’ They were then asked to estimate by sight (in
g) the amount of cannabis/tobacco in each rolling
paper. The weight of the cannabis and tobacco was
recorded to the closest 0.01 g. Weighing took place
under experimenter-blinded conditions and partici-
pants were not given any feedback on their accuracy.
Drug administration and procedure
The effects of (a) active cannabis and active tobacco (CAN
+ TOB), (b) active cannabis + placebo tobacco (CAN),
(c) placebo cannabis + active tobacco (TOB), and (d) pla-
cebo cannabis + placebo tobacco (PLACEBO) were in-
vestigated (doses deﬁned in Table 1; Fig. 1).
On each drug session, participants smoked a joint
(Fig. 1). The inhalation procedure was ﬁxed and timed
by an experimenter to ensure consistency between par-
ticipants and sessions. Participants were asked to inhale
for 4 sec, hold their breath for 8 sec, and then exhale and
break for 30 sec. This sequence was repeated until the
joint was smoked up to a designated line (Fig. 1). Partic-
ipants completed the ‘‘Roll a Joint’’ paradigm on the
baseline session and at *1 h after drug administration
on each drug session. Visual Analogue Scale (VAS) rat-
ings of ‘stoned’ (from not at all [0] to extremely [10])
were taken at 10, +10, +30, +40, and +70min after
drug administration. All participants provided written
informed consent on each occasion. Ethical approval
was given by the UCL Ethics Committee.
Statistical analysis
Bonferroni corrected paired sample t-tests were conducted
between baseline ‘‘actual’’ and ‘‘estimated’’ dose to investi-
gate participants’ accuracy in guessing dose. Linear mixed
models, with a random intercept for ‘‘participant,’’ and
two within subjects factors of cannabis (placebo; active)
and tobacco (placebo; active) were implemented on
both actual and estimated dose. The unstructured
variance/covariance structure was selected.15 The
FIG. 1. Drug administration was conducted
using ‘‘joints,’’ the most common method of
administering cannabis.11 ‘‘Study drug’’ region
contained a mixture of 66.67mg cannabis (active
or placebo) and 311mg tobacco (active or
placebo) dependent on condition (Table 1). The
‘‘placebo tobacco ﬁller’’ region contained 311mg
of placebo tobacco at the bottom of the joint
(nearest to the mouth), which was not smoked.
This ﬁller was added to improve compliance with
the ﬁxed inhalation procedure, as puff volume
typically decreases toward the end of the joint,
probably due to rising heat.18 The stop line is the
point at which participants stopped smoking the
joint, separating the two regions. It was marked
1 cm after the ‘‘study drug’’ region to ensure
complete inhalation.
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dependent variable of actual and estimated cannabis
and tobacco was analyzed in separate models. VAS
‘‘stoned’’ scores were analyzed with a cannabis (pla-
cebo, active) · tobacco (placebo, active) · time (1
[pre-drug] vs. 2–5 [postdrug] ANOVA, which used a
Helmert contrast for time.15
Results
Demographics and drug history
Participants were 24 (50% female) recreational canna-
bis and tobacco cousers. Use of other drugs apart from
cannabis, tobacco, and alcohol was minimal (Table 2).
Twenty-nine percent (n = 7) of participants were regu-
lar tobacco smokers before they ever mixed it with can-
nabis, 46% (n= 11) had tried tobacco, but were not
regular smokers, before mixing it with cannabis, and
25% (n = 6) had never tried tobacco before it was
mixed with cannabis. They self-reported adding
53.52%– 19.38% tobacco in their standard joint. They
self-reported smoking skunk* 49.25%– 30.74% of the
times they smoked cannabis, followed by herbal canna-
bis{ (34.7%– 28.5%) and hash{ (15.95%– 14.10%), re-
spectively.
Actual and estimated dose of cannabis
and tobacco per joint
At baseline, there was a signiﬁcant difference be-
tween the actual and estimated dose of cannabis partic-
ipants would normally smoke (t23 = 3.36, p= 0.003,
d = 0.723) where participants overestimated the dose
twofold (Table 3). In contrast, for tobacco there was
no difference between the actual dose and the estimated
dose (t23 = 1.59, p = 0.125).
Across each drug condition the same effect was ob-
served, suggesting participants were accurate in estimat-
ing the amount of tobacco (all t’s ‡0.93, all p’s‡ 0.087)
but overestimated by roughly 200% the amount of can-
nabis used (all t’s ‡2.62, all p’s£ 0.015).
With regard to the actual dose of cannabis that partic-
ipants rolled after intoxication, there was a main effect of
cannabis (F1,23=5.05, p=0.035). Participants added less
cannabis to their joints after smoking active cannabis
(0.12–0.03) compared to placebo cannabis (0.15–0.02).
There was no main effect of tobacco (placebo: 0.14–
0.03; active 0.13–0.02) or interaction with tobacco.
With regard to the actual dose of tobacco participants
rolled after intoxication, there was a main effect of can-
nabis (F1,23= 22.72, p< 0.001). Participants added less to-
bacco to their joints after active cannabis (0.19– 0.03)
compared to placebo cannabis (0.30– 0.03). There was
no main effect of tobacco (placebo: 0.27– 0.03; active
0.23– 0.03) or interaction with tobacco.
There were no main effects or interactions for the
estimated dose of cannabis ( p’s> 0.05). However, there
was a main effect of cannabis on the estimated dose of
tobacco (F1,23= 6.99, p= 0.014). After active cannabis
(0.23– 0.04), participants correctly estimated they were
using a smaller dose of tobacco than after placebo can-
nabis (0.36– 0.05). There was no main effect of tobacco
(placebo: 0.31– 0.04; active 0.28– 0.04) or interaction
with tobacco.
Subjective effects
Stoned. There was a cannabis X time interac-
tion (F1,23 = 61.17, p < 0.001, Zp2 = 0.74) that revealed
a signiﬁcant increase between cannabis and placebo
from pre- to postdrug (Fig. 2). Predrug, there was no
Table 2. Demographics and Drug History of Participants
N = 24 (mean, SD)
Female, % 50
Age (years) 24.46– 3.96
SDS 0.67– 0.92
(range: 0–3)
FTND 0.33– 0.64
(range: 0–2)
Cannabis + tobacco
Age of first use (years) 16.16– 3.94
Last used (days) 7.92– 9.64
Years used (years) 6.79– 3.94
Days per month 7.75– 4.43
Time to smoke 3.5 g (days) 36.58– 34.47
Lifetime exposures (days) 627– 936
Exposures in the last 90 days (days) 19.58– 11.27
Tobacco
Age of first use (years) 15.71– 1.94
Last used (days) 96.13– 313.26
Years used (years) 6.76– 4.58
Days per month 11.04– 12.68
Cigarettes per day 2.29– 2.74
Lifetime exposures (days) 2834– 7202
Exposures in the last 90 days (days) 29.75– 33.56
Alcohol
Age of first use (years) 13.12– 2.40
Last used (days) 3.46– 3.21
Years used (years) 9.04– 4.57
Days per month 8.80– 5.48
Units per session 5.88– 2.68
Lifetime exposures (days) 821– 557
Exposures in the last 90 days (days) 24.29– 17.93
FTND, Fagerstro¨m Test of Nicotine Dependence; SDS, Severity of
Dependence Scale.
*Skunk refers to high-potency, indoor-grown ﬂoral material of unfertilized plants,
through which energy is diverted from seed production to cannabinoid synthesis
(‘‘sinsemilla’’; meaning ‘‘without seeds’’) (*15% THC).32
{Herbal cannabis refers to low-potency outdoor-grown imported ﬂoral material
(‘‘herbal,’’ ‘‘grass,’’ ‘‘weed’’) (*9% THC).32
{Hash refers to compressed blocks of plant matter (‘‘resin,’’ ‘‘hashish’’) (*5% THC).32
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difference between active and placebo cannabis
( p= 0.575), however, active cannabis increased ‘‘stoned’’
ratings at all time points postdrug (all p’s <0.001). There
was also main effects of cannabis (F1,23= 64.97, p< 0.001,
Zp
2= 0.74) and time (F1,23= 151.30, p< 0.001, Zp2=
0.87). There were no main effects or interactions with
tobacco.
Discussion
This study examined estimated (self-report) and actual
dose of cannabis and tobacco used in a joint. Recrea-
tional cannabis and tobacco users were assessed at
baseline and after intoxication with cannabis and/or
tobacco using a novel ‘‘Roll a Joint’’ paradigm. We used
amatched placebo-cannabis and rolling tobacco to create
an ecological method where their weights, smell, and ap-
pearance closely paralleled the active drugs.
Participants showed a twofold overestimation of the
actual dose of cannabis they added to their joints, while
accurately estimating the dose of tobacco. Importantly,
this effect was replicated across all drug conditions.
This suggests that overestimation of cannabis and ac-
curate estimation of tobacco amounts are a reliable
ﬁnding and impervious to acute intoxication with can-
nabis or tobacco. These data, alongside other studies,
have found an equivalent downward titration either
in the amount they rolled in joints20 or the amount
they inhaled.1 For example, an Australian study that
found participants overestimated the dose of cannabis
to a similar degree, using a cannabis substitute,22 sug-
gests that self-reported dose should be viewed with cau-
tion. One objective measure we would recommend is
to implement this ‘‘Roll a Joint’’ paradigm. Given the
near equivalent overestimation found in the cannabis
Table 3. The Mean, Standard Deviation, Range, and Ratio (Cannabis:Tobacco) of the Estimated Amount
and Actual Weight of Cannabis and Tobacco That Participants Rolled into a Joint During the Baseline Session
and After Each Drug Condition
Cannabis in joint (g) Tobacco in joint (g) Ratio of cannabis to tobaccoa
Estimated Actual Estimated Actual Estimated Actual
Baseline
Mean 0.28 0.14** 0.43 0.35 0.81:1 0.53:1
SD 0.23 0.12 0.25 0.16
Range 0.02–0.90 0.00–0.44 0.10–1.00 0.09–0.74 0.10:1–3.00:1 0.05:1–1.42:1
Placebo
Mean 0.32 0.17** 0.38 0.33 1.12:1 0.63:1
SD 0.29 0.13 0.26 0.17
Range 0.00–1.25 0.00–0.45 0.00–1.00 0.00–0.74 0.05:1–3.50:1 0.05:1–2.00:1
TOB
Mean 0.28 0.14* 0.34 0.27 1.22:1 0.54:1
SD 0.28 0.10 0.26 0.12
Range 0.40–1.00 0.02–0.40 0.00–0.90 0.00–0.46 0.11:1–4.00:1 0.11:1–1.74:1
CAN
Mean 0.25 0.11*** 0.24 0.19 1.23:1 0.70:1
SD 0.20 0.12 0.20 0.14
Range 0.00–0.70 0.00–0.41 0.00–0.60 0.00–0.49 0.1:1 3.33:1 0.05:1–2.33:1
CAN + TOB
Mean 0.32 0.12* 0.22 0.19 1.20:1 1.11:1
SD 0.49 0.19 0.20 0.18
Range 0.00–2.00 0.00–0.59 0.00–0.60 0.00–0.62 0.10:1–3.00–1 0.02:1–5.50:1
Bold text represents signiﬁcant differences between estimated and actual weight. This was the case for cannabis only, and not tobacco.
aN’s range 17–24 as participants were excluded if their response was 0 for either cannabis or tobacco (as a ratio cannot be calculated).
***p £ 0.001, **p £ 0.01, *p£ 0.05.
FIG. 2. VAS ‘‘stoned.’’ Self-ratings of feeling
stoned for all time points before and after each
drug administration. *Represents when drug
administration occurred. Error bars show– standard
error of the mean. VAS, Visual Analogue Scale.
Hindocha, et al.; Cannabis and Cannabinoid Research 2017, 2.1
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amount between this study and the previous study,22
we suggest that use of a substitute, when placebo can-
nabis is not available, is adequate as long as a weight
adjustment is made. We highly recommend that if
users mix cannabis and tobacco, those tobacco estima-
tions are made with real tobacco and recorded, unlike
in previous studies.1,21,22 We encourage investigators
to utilize this methodology, however, precision in
dose estimation remains a problem for other routes
of administration as well, and therefore, further valida-
tion of dose estimation methods is required. Given the
huge variation in popular cannabis routes of adminis-
tration worldwide,11 it would be necessary to validate
this method for other routes (e.g., pipes, bongs, and va-
porizers). There is a stark difference between the meth-
ods by which people smoke cannabis in the United
Kingdom, where this study was conducted and where
smoking a joint with tobacco is the most prevalent
route, and the United States, where smoking cannabis
through a blunt or pipe is common.
After smoking active cannabis, participants re-
duced both the amount of cannabis and tobacco
they put into their joints compared to placebo canna-
bis, suggesting this paradigm is sensitive to acute sa-
tiety. Participants were only able to estimate they
were using less tobacco but not less cannabis, which
may imply they were aware of their satiety to tobacco,
but not cannabis. This may be a consequence of the
lack of information about cannabis due to nontoler-
ated sales, which means a greater level of uncertainty
regarding potency and the total weight of cannabis
bought (e.g., an eighth of an ounce may not actually
be what the user receives) especially for recreational
users.20 Tobacco, however, is sold in standardized
weights and is therefore potentially easier to estimate.
Moreover, it is important to note that participants
were still experiencing acute drug effects at the time
of testing. Tobacco and cannabis differ in their ap-
pearance and typical dose per joint, which may have
inﬂuenced accuracy; however, these factors were not
manipulated and therefore are unlikely to account
for the present results.
In the current turbulent climate of cannabis policy
globally, ﬁnding accurate and standardized cannabis
use metrics is essential to monitor levels of cannabis
and tobacco consumption.28 There has certainly been
some movement toward deﬁning a standard cannabis
unit5 and certainly both frequency and quantity are im-
portant measurements.8 In Europe, the particular issue
of smoking cannabis and tobacco is worrying and
mostly disregarded.29 Understanding how much canna-
bis is in a joint will inform important drug policy discus-
sions6 and improve research outcomes when estimating
dose, especially as self-reported use is often the main
outcome variable used to link cannabis consumption
to health outcomes. It is essential that dose be taken
into account alongside potency measures. Here we
ﬁnd many users were unaware of how much cannabis
they put in their joints and are indeed doubling this ﬁg-
ure. To our knowledge, this is the ﬁrst study to show that
both actual and estimated tobacco in joints is sensitive
to acute cannabis administration indicative of cross-
substance satiety. To investigate this further, use of
smoking topography would be an essential next step.19
Strengths and limitations
This study used a double-blind, placebo-controlled,
four-way, crossover design with recreational users to
investigate actual and estimated dose of cannabis and
tobacco in a joint. A previous study found that recrea-
tional users have a poorer understanding of cannabis
potency than heavy users,20 suggesting these ﬁndings
cannot be extended to, and thus require replication
with, heavier (dependent) users. Indeed, the precision
of all dose measurement is still limited unless the po-
tency of the cannabis is a known factor. Future research
should aim to investigate dose and potency together.
This research was conducted with a moderate number
of recreational cannabis and tobacco users, and this
may limit its generalizability (e.g., to those who do not
mix their cannabis with tobacco or to those who are de-
pendent cannabis users). Furthermore, this study was
not designed to investigate sex differences and therefore
was not adequately powered to address this issue. At the
same time, this ‘‘Roll a Joint’’ paradigm has advantages
over purely self-report measures of dose. We recognize
this study did not have biologically veriﬁed abstinence
or absorption; however, this is unlikely to inﬂuence
our results as the residual cognitive effects of cannabis
rarely last beyond 24h and should be minimal in infre-
quent users.30,31
Conclusions
Self-reported dose per joint is an inaccurate cannabis
use metric. Here we report that a simple, novel ‘‘Roll
a Joint’’ paradigm can overcome these inaccuracies
when collecting cannabis use metrics. Furthermore,
compared to placebo cannabis, active cannabis reduces
the amount of both cannabis and tobacco rolled in a
joint indicative of downward titration.
Hindocha, et al.; Cannabis and Cannabinoid Research 2017, 2.1
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